Profile Picture
  • All
  • AI Mode
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
  • Notebook
  • Top stories
  • 2026 Election
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost recent
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Moderna, COVID

Digest more
Top News
Overview
Impacts
 · 13h
Moderna swings to profit as momentum for cancer vaccine builds
Moderna reported its first quarterly profit in two years, as the US biotech company built on momentum from its successful melanoma vaccine results in August. The Boston-based group said net income swung to $162mn in the third quarter,

Continue reading

MSN · 13h
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
 · 12h · on MSN
Moderna swings to profit, lifts outlook as Covid-19 vaccine demand stabilizes
 · 8h
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises
Moderna MRNA posted third-quarter 2026 earnings per share (EPS) of 38 cents.

Continue reading

 · 13h
Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine
 · 8h
Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction
 · 10h
Moderna Just Gave Investors Yet Another Thing to Cheer About
Moderna earned $162 million, or $0.38 per share, compared with a $200 million loss in the same quarter last year.

Continue reading

Yahoo Finance · 12h
Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook Improves
 · 4h
Moderna Inc (MRNA) Q3 2026 Earnings Call Highlights: Revenue Surges 29% as Guidance Raised and ...
Wisconsin Watch
10h

What you need to know about COVID-19, flu and RSV vaccines

This year, the agency predicts that COVID-19, the flu and RSV could cause a similar number of cases and hospitalizations.  The good news is that immunizations to protect against all three viruses are now available,
4don MSN

RNA-protein interactions could lead to new coronavirus drug targets

A study co-led by a University of California, Riverside, biomedical scientist has identified new targets for coronavirus antiviral drugs, including treatments that may be less vulnerable to the rapid evolution of these viruses.
1d

Health Canada Authorizes Moderna’s mRNA Influenza and Combination Influenza and COVID-19 Vaccines

Canada becomes the first country to authorize both Moderna’s mRNA seasonal influenza vaccine, mFLUSIVA ®, and combination influenza and COVID-19 vaccine, mCOFLU ® CAMBRIDGE, M
The American Journal of Managed Care
10h

Shoulder Injury Rare but More Common After COVID-19 Than Flu Shots

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
6y

Bay Area COVID-19 News

Get the latest COVID-19 news, stories and information on the pandemic, vaccines and mandates around the San Francisco Bay Area and California.
WNYT.com
3h

NYSDOH urges flu, COVID-19, RSV shots before travel

New York Health Commissioner James McDonald urged residents Nov. 5 to get flu, COVID and RSV vaccines as illnesses rise earlier statewide.
The Chosun Ilbo on MSN
1d

Flu and COVID-19 twindemic poses persistent risks for elderly

As temperatures have recently dropped sharply, the risk of respiratory infectious diseases is growing. In particular, with influenza (flu) cases emerging earlier than usual and COVID-19 hospitalizations increasing,
1don MSN

COVID-19 vaccines generated trillions in benefits, far exceeding their estimated costs

Every dollar spent on COVID-19 vaccine development and distribution generated an estimated $81 to $810 in economic value during the first year that vaccines were given, according to new research published in the journal PLOS Medicine.
2026 Midterm Election
View the latest election news
See full coverage
© 2026 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy